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Abstract
Background: Anaphylactoid reactions to iodinated contrast media are relatively common and
potentially life threatening. Opinion is divided as to the utility of medications for preventing these
reactions. We performed a systematic review to assess regimes for the prevention of anaphylactoid
reactions to iodinated contrast media.
Methods: Searches for studies were conducted in the Medline, EMBASE, CINAHL and CENTRAL
databases. Bibliographies of included studies and review articles were examined and experts were
contacted. Randomised clinical trials that examined agents given prior to iodinated contrast
material for the prevention of anaphylactoid reactions were included in the review. The validity of
the included studies was examined using a component approach.
Results: Six studies met the inclusion criteria, but only one of these fulfilled all of the validity
criteria. There were four studies that examined the use of H1 antihistamines, each was used to
prevent anaphylactoid reactions to ionic contrast. The random effects pooled relative risk
demonstrated a significant reduction in the overall rate of anaphylactoid reactions (RR = 0.4, 95%
CI 0.18-0.9, p = 0.027). There were insufficient studies to produce a pooled statistic for the use of
corticosteroids, however regimes of steroids (methylprednisolone 32 mg) given at least six hours
and again two hours prior to the administration of contrast suggested a reduction in the incidence
of anaphylactoid reactions.
Conclusion: In conclusion, there are few high quality randomised clinical trials that have addressed
the question of the optimal methods to prevent allergic type reactions to iodinated radiological
contrast media. Allowing for these limitations, the results suggest that H1 antihistamines given
immediately prior to the administration of ionic contrast may be useful in preventing reactions to
ionic contrast and are suggestive of a protective effect of corticosteroids when given in two doses
at least six hours prior and again two hours prior to the administration of contrast, both ionic and
non-ionic. These agents should be considered for use in patients who are at high risk of an
anaphylactoid reaction to contrast media and for who prophylactic therapy is considered
necessary. Further research is needed before definitive recommendations can be made.
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Background
Advances in diagnostic and interventional radiology have
meant that the number of radiological procedures that
require use of iodinated contrast media have increased in
recent years. The use of iodinated contrast media is asso-
ciated with a risk of adverse reactions, including serious
allergic type reactions which may be life threatening.
Reactions to iodinated contrast range from minor flush-
ing, to severe life threatening anaphylactoid or even fatal
reactions. While the precise mechanism is not well under-
stood, IgE mediated, complement mediated and cell
mediated reactions may play a role [1,2]. The incidence of
adverse reactions to iodinated contrast has been estimated
to be 12.66% for ionic and 3.13% for non-ionic contrast.
Severe reactions which were potentially life-threatening
can occur in 0.04% to 0.22% of cases [3]. Even with a
small incidence such as this, because there are an esti-
mated 50 million procedures involving iodinated contrast
media performed worldwide each year, there are a large
number of patients at risk from potentially life-threaten-
ing reactions[4].
A number of agents have been suggested as being useful
for the prevention of anaphylactoid reactions to iodinated
contrast material, including corticosteroids and H1 and
H2 anti-histamines. There is no current consensus on the
optimal therapy that should be used as preventative
agents, or even if medication should be used now that the
use of non-ionic contrast is almost universal[5,6]. Even
with the widespread use of non-ionic contrast, many radi-
ologists continue to use prophylactic medication to pre-
vent allergic type reactions[7]. Previous guidelines have
used consensus methods rather than evidence-based
methods to make recommendations [6]. While there has
been much recent interest in this area, recent reviews have
not focused specifically on the use of medications in the
prevention of anaphylactoid reactions and have not used
systematic methods to review the literature [1,4]. System-
atic reviews of randomised controlled trials are preferred
to opinion-based guidelines to guide clinical practice, and
may lead to less biased and more reliable recommenda-
tions [8,9]. Systematically searching for and critically
appraising the available primary studies is also important
to allow clinicians the opportunity to evaluate the
strength of the evidence that forms the basis of current
practice, and may point out opportunities for researchers
seeking to improve that evidence.
No previous study has applied systematic methods to
reviewing the literature regarding the prevention of ana-
phylactoid reactions to iodinated contrast media. The aim
of this study was to systematically review the literature
regarding the use of medication in the prevention of ana-
phylactoid reactions to contrast material and to determine
which medication or medications when given prior to the
administration of the contrast media, are associated with
a reduced incidence of these reactions.
Methods
Search strategy
The primary search for relevant studies was conducted in
a number of electronic databases. The MEDLINE database
was searched using the Pubmed interface, and this was
supplemented with searches of MEDLINE, EMBASE,
CINAHL and the Cochrane central register of controlled
trials, using the OVID interface. Search terms were indi-
vidualised for each database and included MESH head-
ings and text words; (anaphylaxis, anaphylactic,
anaphylactoid, hypersensitivity, allergic reaction and
adverse reaction), combined with ("prevention and con-
trol" or prevention) and (contrast media or radiological
contrast). The bibliographies of the included articles and
review articles were examined and attempts were made to
contact experts in the field to identify any otherwise uni-
dentified or unpublished studies. The final search was
conducted up until the June 9th, 2005. There were no lan-
guage restrictions placed on the search.
Inclusion of studies
The titles and abstracts of all reports were reviewed by one
author to identify potentially relevant articles. The full text
reports of potentially relevant studies were then retrieved
and reviewed for consideration for inclusion in the study.
Two authors (AD and AC) independently applied the pre-
determined inclusion criteria to determine eligibility of
the article for inclusion in the review. Disagreements were
resolved by discussion. To be eligible for inclusion the
report had to describe a study:
1. of a medication or medications given prior to the
administration of contrast for a x-ray examination
2. where the x-ray contrast was given as an injection
3. where the main outcome measure was the rate of aller-
gic reactions
4. that was a prospective randomised clinical trial
5. that was reported in English [10]
Validity assessment
The validity of the included studies was assessed using a
component approach, with each study assessed for the
adequacy of randomisation and allocation concealment,
the blinding of outcome assessment and the presentation
of an intention-to-treat analysis and whether the defini-
tions of what constituted an allergic reaction were pro-
spectively defined. Studies that used a method of
randomisation that did not maintain allocation conceal-BMC Medical Imaging 2006, 6:2 http://www.biomedcentral.com/1471-2342/6/2
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ment, such as alternate days or medical record numbers
(i.e. were pseudo-randomised) were recorded as not
maintaining allocation concealment. The validity assess-
ments were conducted by two reviewers (AD and AC),
independently, with disagreements resolved by discus-
sion.
Data extraction
Data were extracted independently, in duplicate by two
authors (AD and AC) onto a specifically designed data
collection form. Disputes were resolved by discussion.
Data were extracted from the reports regarding the popu-
lation under study, the type of contrast used, the prophy-
lactic regime used and the rates of anaphylactoid
reactions. It was decided a-priori to assess the reactions in
two groups where possible, all anaphylactoid reactions
and those which were potentially life threatening such as
bronchospasm, hypotension and airway oedema.
Data synthesis and quantitative analysis
Prophylactic regimes were grouped according to the phar-
macological action of the agents under consideration. Sta-
tistical pooling of results was only considered when there
were three or more studies examining the same prophy-
lactic agent. Statistical heterogeneity was assessed using
the I2 statistic [11] and the χ2 statistic. When heterogeneity
was detected the random effects model of DerSimonian
and Laird was used to pool the results. The potential for
publication bias was assessed using the methods
described by Egger [12]. All statistical calculations were
performed using STATA 8.2 (Statacorp, College Station,
Texas).
Results
A total of 1,099 articles were identified in the initial
search. Of these 1068 were deemed ineligible on review of
the titles and abstracts and 31 were retrieved for full
review. Figure 1 shows the flow of studies and the reasons
for exclusion. Six studies met the inclusion criteria. The
details of the studies including the prophylactic regimes
tested are shown in Table 1. Table 2 shows the results of
the validity assessments for each of the included studies.
Only one study clearly met all of the predefined validity
criteria.
Anti-Histamines
Four studies examined the use of H1-antihistamines [13-
16]. No study met all of the pre-defined validity criteria.
One study [15] included three treatment groups, so for the
purpose of this analysis only the group that received clem-
astine was considered. There was significant clinical heter-
ogeneity as all examined different antihistamine regimes
and the contrast agents were all different. Not surprisingly
there was evidence of significant statistical heterogeneity
amongst the included studies, with the χ2 test p = 0.003
and the I2 = 76.7%. The Egger statistic revealed no evi-
dence for significant publication bias (bias = -2.19, p =
0.32), and inspection of the funnel plot revealed no sig-
nificant asymmetry. Due to the presence of significant sta-
tistical heterogeneity the results from these four studies
were pooled using a random effects model (Figure 2), This
showed a significant reduction in the risk of allergic reac-
tions with the estimate of the relative risk 0.40 (0.18-0.9,
p = 0.027). Separate examination of the reduction in rates
of severe events was not possible, as these events were not
reported in these trials.
Combination of H1 and H2 antihistamines
One study [15] included an experimental group treated
with a combination of clemastine and cimetidine. They
found an incidence of side effects (excluding the subjec-
tive sensation of heat) of 6.1% compared to 12.9% in a
placebo group. This reduction was reported as statistically
significant. Again, there was no reporting in the reduction
of the rates of severe events.
Flow chart showing the flow of included studies and the rea- sons for exclusion of studies Figure 1
Flow chart showing the flow of included studies and the rea-
sons for exclusion of studies.
1,089 Articles identified 
by search 
1058  Reports excluded: 
610   Not related to allergic reactions 
205  Not iodinated contrast media 
96  Not Prospective clinical trials 
44  Contrast not given parenterally  
41  Report not in English  
40  Not related to prevention 
21  Not human subjects 
1  Not a trial of medication 
31 articles potentially 
eligible for inclusion 
Reports excluded: 
23  Not an RCT 
2  Not for prevention of allergic reactions  
6 articles included in the 
systematic review 
Reports excluded: 
2  Data unsuitable for meta-analysis 
4 articles suitable for 
meta-analysis BMC Medical Imaging 2006, 6:2 http://www.biomedcentral.com/1471-2342/6/2
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Corticosteroids
Three studies examined the effect of corticosteroids
[15,17,18]. There were two separate regimes tested. As
only two studies examined each regime, statistical pooling
of the results was not possible. Corticosteroids given
immediately prior to the administration of contrast was
not associated with a significant reduction in the inci-
dence of anaphylactoid reactions. One study recorded an
incidence of adverse reactions of 10.1% in the group given
prednisolone 250 mg five minutes prior to the infusion of
contrast compared to 12.9% in the group given saline
[15], and the other study recorded an incidence of 9.4%
in the group given a single dose of 32 mg of oral methyl-
prednisolone 2 hours prior to the administration of con-
trast, compared to 9.9% in the comparable placebo group
[17].
However when the steroids were given in two doses, at
least six hours prior to, and again two hours prior to the
administration of contrast, the incidence of anaphylac-
toid reactions was reduced. The incidence of reactions was
significantly reduced in patients receiving the methyl
prednisolone 32 mg as a two-dose regime to 6.4% from
9.0% in the placebo group (p < 0.0001) [17]. The rate of
severe reactions in this study was reduced from 0.75 to
0.2% (p = 0.04). Ionic contrast used in this study. The
effect of steroids on patients receiving non-ionic contrast
was examined in a latter study [18]. This study was the
only one to fulfil all of the validity criteria. The rate of
overall reactions to non-ionic contrast in this study was
reduced from 5% in the placebo group to 2% in the group
treated with a two-dose regime of methylprednisolone.
There was a non-statistically significant reduction in the
rate of severe reactions from 0.87% to 0.17% (p = 0.11).
Table 1: Characteristics of the included studies
Study Population Risk Factors for 
Allergic Reactions
Prophylactic 
regime
Contrast agent Reaction
Gates 1972 [13] 2000 adults 
undergoing IVP
History of allergic 
reactions taken, 
patients with positive 
history included
Diphenhydramine 10 
mg ivi 1 minute prior 
to contrast
30–60 ml Renograffin 
60 (Ionic)
Not defined
Small 1982 [14] 220 adults undergoing 
IVP
Patients taking anti-
histamines excluded
Chlorpheniramine 10 
mg sci 15 minutes 
prior to contrast
Not recorded Hives, generalised 
pruritis
Bertrand 1992 [16] 400 adults undergoing 
IVP, CT or lower limb 
venography
Patients with history of 
allergy, atopy, drug 
sensitivity or previous 
reactions to contrast 
excluded
Hydroxyzine 100 mg 
po 12 hours prior to 
contrast
Meglumine ioxaglate 
(Ionic)
Nausea, vomiting, 
hives, urticaria, 
flushing, facial oedema, 
wheezing, dyspnoea, 
laryngeal oedema, 
hypotension, death
Ring 1985 [15] 800 adults undergoing 
IVP
Patients with previous 
life-threatening 
contrast reaction 
excluded
1. Prednisolone 250 
mg ivi, 5 minutes prior 
to contrast
2. Clemastin 0.03 mg/
kg ivi, 5 minutes prior 
to contrast
3. Clemastin 0.03 mg/
kg ivi + cimetidine 5 
mg/kg vi, 5 minutes 
prior to contrast
100 ml meglumine 
amidotrizoate (ionic)
Flush, urticaria, 
angioedema, 
respiratory symptoms, 
vomiting, tachycardia, 
hypotension
Lasser 1987 [17] 6763 adults
undergoing IVP or 
contrast enhanced CT
Patients with previous 
severe reaction 
excluded. Patients with 
general allergies, drug 
allergies and previous 
non life threatening 
reactions were 
included
1. Methylprednisolone 
32 mg po two hours 
prior to contrast
2. Methylprednisolone 
32 mg o the night 
before + two hours 
prior to contrast
Various ionic contrast 
agents
Grade 1: emesis, 
nausea, sneezing, 
vertigo Grade II: Hives, 
fever, hills, Grade III: 
Shock, bronchospasm, 
laryngospasm, 
laryngeal oedema, loss 
of consciousness, 
angioedema
Lasser 1994 [18] 1155 adults 
undergoing IVP or 
contrast enhanced CT
Patients with allergies 
including previous 
reactions to contrast 
were included
Methylprednisolone 32 
mg po the night before 
and two hours prior to 
the contrast
Iohexol, Ioversol (non-
ionic)
As per Lasser 1987BMC Medical Imaging 2006, 6:2 http://www.biomedcentral.com/1471-2342/6/2
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Discussion
With the increasing numbers of radiological procedures
that require the use of intravenous contrast, the preven-
tion of anaphylactoid reactions is likely to remain an
important issue both for radiologists performing the pro-
cedures and the physicians referring patients for these
investigations. This systematic review found that there
were relatively few studies that examined treatments to
prevent anaphylactoid reactions to intravenous contrast,
and that the studies that are available are generally not of
a very high quality. Allowing for these limitations, the
results suggest that H1 antihistamines given immediately
prior to the administration of ionic contrast may be useful
in preventing reactions to ionic contrast and are suggestive
of a protective effect of corticosteroids when given in two
doses at least six hours prior and again two hours prior to
the administration of contrast, both ionic and non-ionic.
These agents should be considered for use in patients who
are at high risk of an anaphylactoid reaction to contrast
media and for who prophylactic therapy is considered
necessary.
As the overall incidence of anaphylactoid reactions to
contrast media is low, the use of prophylactic medication
is likely to be restricted to those most at risk, such as
patients with previous reactions to contrast and those
with asthma [19]. The protective effect of H1 antihista-
mines and corticosteroids in high-risk patients has been
demonstrated in non-randomised studies. The use of
prednisone 50 mg given 13, 7 and 1 hour and diphenhy-
dramine 50 mg 1 hour prior to the administration of non-
ionic contrast in 120 patients who had previous reactions
to contrast was associated with only one minor reaction
[20]. For emergency procedures, the use of hydrocortisone
in a doses of 100–250 mg given intravenously as soon as
the need for the examination was established and then
every 4 hours until the contrast examination was com-
pleted, combined with diphenhydramine 50 mg given
immediately prior to the examination was associated with
no allergic reactions in a series of nine patients with pre-
vious allergic reactions to contrast [21]. There are however
reports of patients who have had repeat reactions in spite
of premedication [22-24].
The incidence of allergic reactions is also dependent on
the type of contrast agent used. The use of non-ionic con-
trast has been associated with a lower risk of allergic reac-
tions[19]. There is still a small but significant risk of
serious allergic reactions when non-ionic agents are used
[3,25]. As the study by Lasser[18] was the only study to
examine the effect of prophylactic treatment for patients
receiving non-ionic contrast, the results of this review
would suggest, without being definitive, that two doses of
corticosteroids be used as prophylaxis, at least for patients
at high risk of reactions. This is the approach being
already used by some clinicians[7]. Corticosteroids would
not however be expected to prevent all reactions, espe-
cially those mediated by chemotoxic reactions.
There are a number of limitations to the results that can be
drawn from this study. Firstly, the quality of the included
studies was less than optimal. The strength of a meta-anal-
ysis is reliant on the quality of the included studies. When
the primary studies are of a poor quality, no statistical
manipulation can make up for the inherent potential bias.
Secondly, there was significant heterogeneity with regards
to the prophylactic agents used with each study using a
different agent, timing and route of administration, the
Forest plot showing the effect of prophylactic H1 antihista- mines on the incidence of anaphylactoid reactions to iodi- nated contrast media Figure 2
Forest plot showing the effect of prophylactic H1 antihista-
mines on the incidence of anaphylactoid reactions to iodi-
nated contrast media.
  Risk ratio
 H1-Antihistamine Better   Control Better
 .05  .1  .25  .5  1  2  4  8
 Study
  Risk ratio
 (95% CI)
 No. of events
 H1-Antihistamine  Control
 Gates   0.58 ( 0.43, 0.80)  53/913  108/1087
 Small   0.12 ( 0.02, 0.90)  1/78  15/142
 Ring   0.93 ( 0.55, 1.59)  23/191  25/194
 Bertrand   0.08 ( 0.02, 0.33)  2/200  25/200
 Overall   0.40 ( 0.18, 0.90)  79/1382  173/1623
Table 2: Methodological quality assessment of included studies
Study Allocation concealment Blinding Intention to treat 
analysis
Predefined outcomes
Gates 1972 [13] No No Unclear No
Small 1982 [14] Unclear Unclear Unclear No
Bertrand 1992 [16] Unclear "Double-blind" Yes Yes
Ring 1985 [15] Unclear "Single" No Unclear
Lasser 1987 [17] Yes Yes Unclear Yes
Lasser 1994 [18] Yes Yes Yes YesBMC Medical Imaging 2006, 6:2 http://www.biomedcentral.com/1471-2342/6/2
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contrast agent used and the populations under investiga-
tion. Thirdly, while combinations of medications are
often recommended [6], only one of the studies identified
in this review examined the effect of combinations of
medications. Fourthly, most of the studies included in
this review did not specifically examine the effect of the
prophylactic regimes in high-risk patients, or the effects of
these therapies for patients receiving non-ionic contrast,
the specific population for whom prophylactic therapy is
generally aimed [6]. These factors limit the conclusions
that can be drawn from this study.
One of the most important findings of this review is that
there is little current high-quality evidence that clinicians
could rely on to guide their practice. By identifying the
gaps in the evidence using systematic methods, it is hoped
that this review may form the foundation for further stud-
ies to improve knowledge in this area. While randomised
clinical trials are often viewed as the gold standard for evi-
dence for preventative or therapeutic interventions, the
difficulty in performing large randomised control trials to
examine this issue may be prohibitive. It has been argued
that well conducted observational studies can produce
estimates of treatment effect that reflect the results pro-
duced by randomised clinical trials [26,27]. Large prop-
erly designed cohort or case-control studies would be
more feasible and may be the appropriate study designs to
shed further light on these issues. Future studies should
concentrate on high-risk patients receiving non-ionic con-
trast. Possible research designs could include large, multi-
national co-operative purpose-designed prospective data-
bases. The need for such reporting has been recently high-
lighted[28]. Such case control or cohort studies could
help in deciding whether further prospective randomised
double blind placebo controlled trials are necessary and
feasible.
Conclusion
In conclusion, there are few high quality randomised clin-
ical trials that have addressed the question of the optimal
methods to prevent allergic type reactions to iodinated
radiological contrast media. There is only one underpow-
ered study that examines preventative regimes for ionic
contrast agents. This systematic review found that the use
of H1 antihistamines and corticosteroids is supported by
the available trials that have examined treatments to pre-
vent anaphylactoid reactions to radiological contrast
media. However, further research into the appropriate
populations to offer this treatment to and the optimal
combination of agents to use needs to be considered
before recommendations could be made with confidence.
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